Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights

Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD Recent Achievements and Upcoming Milestones: SOL-1 remains on track for 1Q 2026 topline data SOL-R rescue criteria streamlined and simplified with topline data expected in 1H 2027 Planning to incorporate single long-term extension study for both SOL trials Ocular to host Investor Day on Tuesday, September 30, 2025, in New York City Raised gross proceeds of approximately $97 million in June 2025 through exis ...